Pharma is stepping up acquisition activity, with coverage describing a surge in biotech deals valued at $1 billion or more over the last six months. The report cites 32 such transactions and about $123 billion in spending, noting that activity has outpaced prior-year totals in roughly half the time. The piece further characterizes 2025 as already heavy on blockbuster M&A—26 large deals totaling $112 billion—setting the stage for why further purchases may remain a dominant strategy for portfolio replenishment. For biotech companies, the environment underscores the importance of clinical differentiation, platform defensibility, and near-term catalysts that can support valuation in a fast-moving M&A window.